Welcome to our dedicated page for Disc Medicine news (Ticker: IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.
Disc Medicine Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company pioneering novel therapies for hematologic disorders through innovative research in iron metabolism and red blood cell biology. This page serves as the definitive source for verified corporate developments, research milestones, and regulatory updates.
Investors and researchers will find timely updates on clinical trials for lead candidates including bitopertin (targeting erythropoietic protoporphyria) and DISC-0974 (for anemia management). Our curated news collection covers essential updates, partnership announcements, and scientific presentations without speculative commentary.
Key content categories include phase trial results, FDA communications, intellectual property developments, and peer-reviewed research findings. All materials are vetted for accuracy and relevance to therapeutic advancements in hematology.
Bookmark this page for streamlined access to IRON's latest progress in developing first-in-class therapies that address unmet needs in iron-related disorders. Check regularly for objective updates on pipeline candidates and corporate strategy.
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company, announced that its CEO, John Quisel, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 2:30 p.m. ET. The event aims to highlight the company's innovative treatments for serious hematologic diseases, focusing on red blood cell biology and iron homeostasis.
The fireside chat will be accessible via a live webcast on the investor relations section of the company's website, with an archived replay available post-event. Disc Medicine is dedicated to developing novel therapies targeting fundamental biological pathways in hematologic diseases.
Disc Medicine, a clinical-stage biopharmaceutical company (NASDAQ:IRON), announced a virtual KOL investor event scheduled for April 25, 2023, to discuss erythropoietic protoporphyria (EPP). This rare and severe disease is caused by mutations in the heme biosynthesis pathway. The event will feature presentations from experts who will address the disease's epidemiology, pathophysiology, and unmet patient needs. Leadership will also outline development plans for bitopertin, an investigational therapy aimed at treating EPP. Currently, there is no cure for EPP, and only one FDA-approved treatment exists. The event will be webcast live, with a replay available for 90 days. For further details, visit Disc's investor webpage.
Disc Medicine, a clinical-stage biopharmaceutical company, completed a reverse merger with Gemini Therapeutics and debuted on Nasdaq as IRON. It ended 2022 with approximately $194.6 million in cash and cash equivalents. The company has initiated two Phase 2 trials for bitopertin targeting erythropoietic protoporphyria and expects initial data in 2023. Additionally, it completed a Phase 1 study of DISC-0974 and began new studies in patients with myelofibrosis and chronic kidney disease. The net loss for 2022 was $46.8 million, up from $36.0 million in 2021, due to increased operating costs.
Disc Medicine (NASDAQ:IRON) announced its collaboration with the National Heart Lung and Blood Institute to conduct a phase 2 clinical trial of bitopertin in patients with Diamond-Blackfan anemia (DBA). This trial aims to evaluate the efficacy of bitopertin, an investigational drug designed to modulate heme biosynthesis, which could potentially address heme accumulation in DBA patients. The study will be sponsored by the NHLBI and is anticipated to begin in mid-2023. DBA is a rare inherited blood disorder characterized by severely reduced red blood cell production, often requiring lifelong management.
